Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Sugimoto, H. et al. Nat. Med. 18, 396–404 (2012).

  2. 2

    Attisano, L., Wrana, J.L., Lopez-Casillas, F. & Massague, J. Biochim. Biophys. Acta 1222, 71–80 (1994).

  3. 3

    Wrana, J.L. Miner. Electrolyte Metab. 24, 120–130 (1998).

  4. 4

    Ehrlich, M., Horbelt, D., Marom, B., Knaus, P. & Henis, Y.I. Cell. Signal. 23, 1424–1432 (2011).

  5. 5

    Nickel, J., Sebald, W., Groppe, J.C. & Mueller, T.D. Cytokine Growth Factor Rev. 20, 367–377 (2009).

  6. 6

    Harrison, C.A. et al. Mol. Cell. Endocrinol. 225, 19–24 (2004).

  7. 7

    Knaus, P. & Sebald, W. Biol. Chem. 382, 1189–1195 (2001).

  8. 8

    Greenwald, J. et al. Mol. Cell 11, 605–617 (2003).

  9. 9

    ten Dijke, P. et al. J. Biol. Chem. 269, 16985–16988 (1994).

  10. 10

    Bernkop-Schnürch, A. & Schmitz, T. Curr. Drug Metab. 8, 509–517 (2007).

  11. 11

    Burton, P.S., Conradi, R.A., Ho, N.F., Hilgers, A.R. & Borchardt, R.T. J. Pharm. Sci. 85, 1336–1340 (1996).

  12. 12

    Bellmann-Sickert, K. & Beck-Sickinger, A.G. Trends Pharmacol. Sci. 31, 434–441 (2010).

  13. 13

    Dewulf, N. et al. Endocrinology 136, 2652–2663 (1995).

Download references

Author information

Correspondence to Malcolm Whitman.

Ethics declarations

Competing interests

M.W. is an inventor on patent applications USPTO 13/058,486 and 61/586,271 with potential relevance to the treatment of fibrosis.

Rights and permissions

Reprints and Permissions

About this article

Further reading